Creo Medical (LSE:CREO) has agreed to sell its UK-based manufacturing division to a newly established company led by its current manufacturing management team, as part of a management buyout. Around 25 employees will transfer to the new entity, with production of Creo’s devices continuing under an outsourced model. The transaction reflects the company’s transition toward a leaner structure focused on product development and commercialisation, while maintaining operational continuity and technical expertise.
The outsourcing arrangement is expected to deliver annual cost savings exceeding £1 million, representing an additional 15% reduction based on the FY25 closing run-rate on a pro forma basis. This builds on an estimated 40% cost reduction already achieved since FY24. By maintaining a close relationship with the new manufacturing business—where CEO Craig Gulliford will take on a non-executive role—Creo aims to scale production efficiently while concentrating resources on innovation and sales growth, reinforcing its position in the advanced medical device sector.
Despite these operational efficiencies, the company’s financial outlook remains under pressure, with declining revenues, significant losses, and continued cash outflows. Market indicators offer some support, with a strong upward trend and positive MACD, although a high RSI suggests the stock may be overbought in the near term. The overall valuation impact is unclear, as key metrics such as price-to-earnings ratio and dividend yield are not currently available.
More about Creo Medical
Creo Medical Group is a UK-based medical technology company specialising in minimally invasive electrosurgical devices used in endoscopic procedures for pre-cancerous and cancerous conditions. Its CROMA platform, built on Kamaptive technology, combines multiple energy sources—including radiofrequency and microwave—into a single system to enable precise cutting, coagulation, dissection, and ablation. The company is focused on advancing a portfolio of patented solutions aimed at improving clinical outcomes while reducing the invasiveness and cost of surgical and endoscopic treatments.
Leave a Reply